secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125334
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q3 net loss narrows to $21.9M; tab-cel PDUFA Jan 15, 2025; CLO departs
----------------------------------------------------------------------------

- Net loss $21.9M ($2.93/share) vs $69.8M ($16.40) YoY; revenue rose to $40.2M from $2.1M.
- Cash, equivalents & investments $67.2M; net cash used in ops $4.0M vs $51.3M; cash runway into 2027.
- Tab-cel BLA on track; PDUFA Jan 15, 2025; no advisory committee; potential $60M milestone from Pierre Fabre.
- First patient dosed in ATA3219 NHL study; initial data Q1 2025. Lupus nephritis study start by year-end; data mid-2025.
- Chief Legal Officer Amar Murugan departed Nov 8; consulting role at $250/hr; severance and bonuses tied to tab-cel milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/0000950170-24-125334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-20241108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer